Thrombocytopenia
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Thrombocytopenia

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Thrombocytopenia Local Doctors?
Elite in Thrombocytopenia
Elite in Thrombocytopenia

Duke Hematology Clinic - Clinic 1E

40 Duke Medicine Cir, 
Durham, NC 
Experience:
37+ years
Languages Spoken:
English
Offers Telehealth

Gowthami Arepally is a Hematologist practicing medicine in Durham, North Carolina. She has been practicing medicine for over 37 years. Dr. Arepally is rated as an Elite provider by MediFind in the treatment of Thrombocytopenia. She is also highly rated in 25 other conditions, according to our data. Her clinical expertise encompasses Thrombocytopenia, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), and Sickle Cell Disease. Dr. Arepally is board certified in American Board Of Internal Med, Hematology.

Elite in Thrombocytopenia
Hematology
Elite in Thrombocytopenia
Hematology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
Experience:
44+ years
Languages Spoken:
English
Offers Telehealth

Keith Mccrae is a Hematologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 44 years. Dr. Mccrae is rated as an Elite provider by MediFind in the treatment of Thrombocytopenia. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Antiphospholipid Syndrome, Venous Thromboembolism (VTE), Hereditary Hemorrhagic Telangiectasia, Thrombocytopenia, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Thrombocytopenia
Elite in Thrombocytopenia

Duke Hematology Clinic - Clinic 1E

40 Duke Medicine Cir, 
Durham, NC 
Languages Spoken:
English
Offers Telehealth

I primarily see patients who have a variety of rare bleeding and clotting disorders. I see both older and younger patients and also provide help when patients need to transition to and away from blood thinners. Doctors usually refer patients to me. I try to work with each patient so they understand why they are seeing me and what is going on with their body. I enjoy when a patient can leave my office with a complete understanding of what is going on and what they need to do to get better. As a young child, I had bad allergies and spent much time in the doctor’s office. As a frequent patient, I enjoyed spending time around medicine. As I entered college, I found that I enjoyed chemistry and that hematology allowed me to combine lab work with patient care. Dr. Ortel is rated as an Elite provider by MediFind in the treatment of Thrombocytopenia. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Venous Thromboembolism (VTE), Antiphospholipid Syndrome, Thrombocytopenia, Thrombectomy, and Thalamotomy. Dr. Ortel is board certified in American Board Of Internal Med, Hematology and American Board Of Internal Med, Internal Medicine.

What are the latest Thrombocytopenia Clinical Trials?
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

Summary: Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases per million population per year. aHUS is a thrombotic microangiopathy (TMA) commonly caused by dysregulation of the complement system, affecting several organs, especially the kidneys. aHUS can be familial or sporadic, and approximately 50%...

Match to trials
Find the right clinical trials for you in under a minute
Get started
AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA

Summary: This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP